Trust that the vaccine will be made first so that it is available to those who want it most, regardless of their ability to pay.
Vardhan also said the government is taking all mandatory precautions to conduct human trials of the vaccine and that officials are developing a detailed strategy on how to vaccinate the majority of the population.
“Problems such as vaccine safety, cost, equity, bloodless chain requirements, production delays, etc. , are also intense,” he said.
Regarding the availability of the vaccine and its authorization, Vardhan reported that the Centre provides for an emergency authorization for COVID-19 vaccination, i. e. for the elderly and those in high-risk settings. This will be done after a consensus has been reached. “, he said, according to an official statement.
To allay fears about the protection side of vaccines, he said, “I will be the first to offer the COVID vaccine, if other people have a confidence deficit. “
He also noted that an effective vaccine will help to identify the opposite immunity to COVID-19 at a much faster rate compared to herbal infection. A consensus was expected to emerge in the coming months on the desired point of protective herd immunity in any community, he said.
In developing candidate vaccines and their progression in India, Vardhan added that the Department of Biological Technology (DBT) and the Medical Research Council of India (ICMR) have been proactive in responding to the emerging scenario for the advancement of candidate vaccines. With the Coalition for Epidemic Preparedness Innovations (CEPI) and multi-phase trials are being conducted for various vaccines in laboratories (private or public) and hospitals in India.
The Minister of Health interacted and answered questions from his social media fans on the “Sunday Samvad” platform.
India currently has 3 candidate vaccines, adding the country’s first indigenous candidate vaccine, Covaxin, which are at other stages of the clinical study, ICMR (Prof) scientist Balram Bhargava previously reported. “So, right now, we have 3 Indian Candidate Vaccines found at other stages of a clinical study. Studies for Phases 1 and 2 will have very early protection and efficacy. “
The Covid-19 Covaxin candidate vaccine, developed through ICMR and Bharat Biotech, is recently found in I/II human trials and is currently being tested in 12 institutes across India.
For the candidate vaccine developed through AstraZeneca and the University of Oxford, the main Indian Serum Pharmaceutical Institute (SII) said it would resume in India once the Indian Comptroller General (DCGI) gave it the required approval.
AstraZeneca PLC discontinued the coronavirus (recombinant) vaccine trial on 6 September while a volunteer had an unexplained disease. He also reported that clinical trials had been suspended in other countries, adding the United States, the United Kingdom, Brazil and South Africa. .
The third is a DNA vaccine from pharmaceutical giant Zydus Cadila. He completed the Phase 1 exam in India and started the Phase 2 exam at 11 sites and is progressing well.
Click here to read that Mint ePapermint is now on Telegram. Join the mint channel in your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any email from us, check your spam folder.